OmniAb (OABI) Stock Forecast: StockMap's 2-Week Call
OABI stock forecast: StockMap's model makes no two-week call on OmniAb after the Nov 13 close: its evidence is split, 5 reasons for and 10 against. Too few two-week windows graded to judge yet.
OmniAb last closed at $4.91, -0.81% on the session.
Against the IVW growth benchmark the position is +0.10% over the forecast window.
OmniAb's market cap is $716.16M as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 15 (too close to call).
Where OABI sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 33%.
10 daily calls for OABI so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks OmniAb in the 28th percentile on return on equity, where 100 is best.
OmniAb is classified under Health Care / Life Sciences Tools & Services.
StockMap tracks OmniAb as the 33rd largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.
Across that group the current two-week reads are 25 Neutral, 13 Moderate Outperform, 3 Moderate Underperform and 1 Strong Underperform.
On that composite OmniAb ranks 18th of 42 in the group, against a group median of +0.13.